To summarize, this characteristic makes PSMA excellent target of prostate cancer, because it is (1) primarily expressed in the prostate, (2) abundantly expressed as protein at all stages of the disease, (3) presented at the cell surface but not released into the circulation, (4) up-regulated in metastatic disease, (5) associated with enzymatic activity, and (7) internalized after antibody binding by receptor-mediated endocytosis. Here, FOLH1 is linked to prostate cancer.